Dermatomyositis‐like syndrome and HMG‐CoA reductase inhibitor (statin) intake
- 7 September 2004
- journal article
- case report
- Published by Wiley in Muscle & Nerve
- Vol. 30 (6), 803-807
- https://doi.org/10.1002/mus.20127
Abstract
A patient developed an adult-onset dermatomyositis-like syndrome characterized by skin rash and progressive proximal muscle weakness concurrent with the intake of simvastatin. Despite discontinuation of the statin, symptoms progressed and required conventional steroid therapy for remission. The association between statins and the development of a musculocutaneous syndrome closely resembling dermatomyositis in susceptible subjects is poorly understood and has been reported rarely. The purpose of this report is to provide additional support for this pathological association. Since the population receiving statins is large and rapidly growing, caregivers are urged to be alert regarding the early recognition and proper care of the spectrum of neuromuscular complications linked to statin intake.Keywords
This publication has 35 references indexed in Scilit:
- Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cellsBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1996
- Musculoskeletal Manifestations During Simvastatin TherapyRheumatology, 1993
- Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled StudyThe Journal of Clinical Pharmacology, 1993
- Skin Lesions due to Treatment with Simvastatin (Zocor®)Dermatology, 1993
- LOVASTATIN, ISOPRENES, AND MYOPATHYThe Lancet, 1989
- Rhabdomyolysis in Patients Receiving Lovastatin after Cardiac TransplantationNew England Journal of Medicine, 1988
- Cimetidine and PolymyositisNew England Journal of Medicine, 1983
- Torsional Fractures and the Third Dimension of Fracture ManagementSouthern Medical Journal, 1980